‘Fusogenic’ neurosurgery let paralysed pigs walk again – are we next?
Researchers say a surgery that let pigs with completely severed spinal cords walk again may lead to human trials, and then perhaps even full head or brain transplants. Columnist Helen Thomson is intri
Researchers say a surgery that let pigs with completely severed spinal cords walk again may lead to human trials, and then perhaps even full head or b
Read Full Story at New Scientist →Why This Matters
The landmark "fusogenic" neurosurgery breakthrough isn't just about restoring mobility—it challenges the fundamental biological limits of spinal cord regeneration. If human trials confirm these results, the implications extend far beyond paralysis, potentially redefining the boundaries of neurological recovery and what medicine deems irreversible.
Background Context
Spinal cord injuries have long been considered permanent due to the central nervous system's limited self-repair capacity, a doctrine cemented by decades of research into glial scarring and inhibitory molecular pathways. The technique's reliance on "fusogenic" agents—molecules that promote cellular fusion—represents a radical departure from conventional approaches like stem cell therapy or electrical stimulation.
What Happens Next
Ethical oversight will likely become the primary bottleneck as researchers navigate the leap from porcine models to human subjects, particularly given the procedure's invasive nature and the risks of immune rejection or unintended neural cross-talk. Meanwhile, the prospect of head or brain transplants—once relegated to speculative fiction—may no longer seem so far-fetched, forcing regulators to confront questions about identity and consent in ways never before codified.
Bigger Picture
This work sits at the intersection of three accelerating trends: the convergence of bioengineering and AI-driven surgical precision, the growing investor appetite for "moonshot" medical interventions, and a cultural shift toward challenging the inevitability of degenerative conditions. It also underscores a broader reckoning with the ethical frameworks governing human enhancement—where the line between therapy and augmentation may soon need redrawing.
